{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:52Z","timestamp":1777593652414,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mucopolysaccharidosis (MPS) is caused by the deficiency of a specific hydrolytic enzyme that catalyzes the step-wise degradation of glycosaminoglycans (GAGs). In this study, we propose an empirical method to calculate levels of GAG-derived disaccharides based on the quantity (peak areas) of chondroitin sulfate (CS) with the aim of making a diagnosis of MPS more accurate and reducing the occurrence of false positive and false negative results. In this study, levels of urinary GAG-derived disaccharides were measured in 67 patients with different types of MPS and 165 controls without MPS using a tandem mass spectrometry assay. Two different methods of reporting GAG-derived disaccharides were assessed; normalization to urinary CS (in \u03bcg\/mL), and normalization to \u03bcg\/mg creatinine. CS-normalization yielded more consistent values than creatinine-normalization. In particular, levels of urinary dermatan sulfate (DS), heparan sulfate (HS), and keratan sulfate (KS) significantly varied because of changes in urine creatinine levels, which were proportional to age but inversely proportional to DS, HS, and KS measurements. Using CS-normalization revealed the actual status of DS, HS, and KS without the influence of factors such as age, urine creatinine, and other physiological conditions. It could discriminate between the patients with MPS and controls without MPS, and also to evaluate changes in GAG levels pre- and post-enzyme replacement therapy.<\/jats:p>","DOI":"10.1038\/s41598-019-46829-x","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T13:07:35Z","timestamp":1563973655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Normalization of glycosaminoglycan-derived disaccharides detected by tandem mass spectrometry assay for the diagnosis of mucopolysaccharidosis"],"prefix":"10.1038","volume":"9","author":[{"given":"Hsiang-Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Ting","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuan-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Fa","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru-Yi","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuan-Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Kuang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"46829_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S0957-5839(97)80195-9","volume":"7","author":"GTN Besley","year":"1997","unstructured":"Besley, G. T. N. & Wraith, J. E. Lysosomal disorders. Current Paediatrics. 7, 128\u2013134 (1997).","journal-title":"Current Paediatrics."},{"key":"46829_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0957-5839(96)80065-0","volume":"6","author":"JE Wraith","year":"1996","unstructured":"Wraith, J. E. Mucopolysaccharidoses. Current Paediatrics. 6, 74\u201379 (1996).","journal-title":"Current Paediatrics."},{"key":"46829_CR3","unstructured":"Neufield, E. F., & Muenzer, J. The mucopolysaccharidoses. In: Scriver, C., Beaudet, A. L., Valle, D., Sly, W. S. eds The metabolic and molecular bases of inherited disease, Vol. 136, 8th edn. New York, NY: McGraw-Hill, 3421\u201352 (2001)."},{"key":"46829_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-21","volume":"9","author":"HY Lin","year":"2014","unstructured":"Lin, H. Y. et al. Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet J Rare Dis. 9, 21 (2014).","journal-title":"Orphanet J Rare Dis."},{"key":"46829_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/atm.2018.11.39","volume":"6","author":"A Sun","year":"2018","unstructured":"Sun, A. Lysosomal storage disease overview. Ann Transl Med. 6, 476 (2018).","journal-title":"Ann Transl Med."},{"key":"46829_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-72","volume":"6","author":"M Scarpa","year":"2011","unstructured":"Scarpa, M. et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 6, 72 (2011).","journal-title":"Orphanet J Rare Dis."},{"key":"46829_CR7","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.1542\/peds.2007-1350","volume":"121","author":"R Martin","year":"2008","unstructured":"Martin, R. et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 121, e377\u2013386 (2008).","journal-title":"Pediatrics."},{"issue":"Suppl 455","key":"46829_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1651-2227.2007.00212.x","volume":"96","author":"IV Schwartz","year":"2007","unstructured":"Schwartz, I. V. et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr. 96(Suppl 455), 63\u201370 (2007).","journal-title":"Acta Paediatr."},{"key":"46829_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ymgmr.2014.04.001","volume":"1","author":"P Patel","year":"2014","unstructured":"Patel, P. et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter Syndrome. Mol Genet Metab Rep. 1, 184\u2013196 (2014).","journal-title":"Mol Genet Metab Rep."},{"key":"46829_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith, J. E. et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 144, 581\u2013588 (2004).","journal-title":"J Pediatr."},{"key":"46829_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1517\/21678707.2013.846853","volume":"1","author":"S Tomatsu","year":"2013","unstructured":"Tomatsu, S. et al. Therapies of mucopolysaccharidosis IVA (Morquio A syndrome). Expert Opin Orphan Drugs. 1, 805\u2013818 (2013).","journal-title":"Expert Opin Orphan Drugs."},{"key":"46829_CR12","first-page":"89","volume":"3","author":"C Decker","year":"2010","unstructured":"Decker, C. et al. Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med. 3, 89\u2013100 (2010).","journal-title":"J Pediatr Rehabil Med."},{"key":"46829_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ymgme.2014.05.013","volume":"114","author":"S Tomatsu","year":"2015","unstructured":"Tomatsu, S. et al. Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions? Mol Genet Metab. 114, 195\u2013202 (2015).","journal-title":"Mol Genet Metab."},{"key":"46829_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ymgme.2017.11.015","volume":"123","author":"CJ Hendriksz","year":"2018","unstructured":"Hendriksz, C. J. et al. Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study. Mol Genet Metab. 123, 127\u2013134 (2018).","journal-title":"Mol Genet Metab."},{"key":"46829_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer, J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 111, 63\u201372 (2014).","journal-title":"Mol Genet Metab."},{"key":"46829_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0344-4","volume":"10","author":"NA Al-Sannaa","year":"2015","unstructured":"Al-Sannaa, N. A. et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis. 10, 131 (2015).","journal-title":"Orphanet J Rare Dis."},{"key":"46829_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0135-3","volume":"9","author":"CK Chuang","year":"2014","unstructured":"Chuang, C. K. et al. A modified liquid chromatography\/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 9, 135 (2014).","journal-title":"Orphanet J Rare Dis."},{"key":"46829_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2010.09.003","volume":"102","author":"C Auray-Blais","year":"2011","unstructured":"Auray-Blais, C. et al. Efficient analysis of urinary glycosaminoglycans by LC-MS\/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab. 102, 49\u201356 (2011).","journal-title":"Mol Genet Metab."},{"key":"46829_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ymgme.2016.09.005","volume":"120","author":"F Kubaski","year":"2017","unstructured":"Kubaski, F. et al. Glycosaminoglycans detection methods: Applications of mass spectrometry. Mol Genet Metab. 120, 67\u201377 (2017).","journal-title":"Mol Genet Metab."},{"key":"46829_CR20","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.4155\/bio.11.172","volume":"3","author":"LA Martell","year":"2011","unstructured":"Martell, L. A. et al. Validation of an LC-MS\/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis. 3, 1855\u20131866 (2011).","journal-title":"Bioanalysis."},{"key":"46829_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/bmc.760","volume":"21","author":"T Oguma","year":"2007","unstructured":"Oguma, T., Tomatsu, S. & Okazaki, O. Analytical method for determination of disaccharides derived from keratan sulfates in human serum and plasma by high-performance liquid chromatography\/turbo-ionspray ionization tandem mass spectrometry. Biomed Chromatogr. 21, 356\u2013362 (2007).","journal-title":"Biomed Chromatogr."},{"key":"46829_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/gim.2014.25","volume":"16","author":"M Beck","year":"2014","unstructured":"Beck, M. et al. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med. 16, 759\u2013765 (2014).","journal-title":"Genet Med."},{"key":"46829_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0635-z","volume":"12","author":"J Muenzer","year":"2017","unstructured":"Muenzer, J. et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 12, 82 (2017).","journal-title":"Orphanet J Rare Dis."},{"key":"46829_CR24","unstructured":"Newman, D. J. & Price, C. P. Renal function and nitrogen metabolites. In Tietz Textbook of Clinical Chemistry. Third edition. Edited by CA Burtis, ER Ashwood. Philadelphia, WB Saunders, pp 1204-1270 (1999)."},{"key":"46829_CR25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/8904_2014_311","volume":"16","author":"T Shimada","year":"2014","unstructured":"Shimada, T. et al. Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII. JIMD Rep. 16, 15\u201324 (2014).","journal-title":"JIMD Rep."},{"key":"46829_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","volume":"57","author":"H Zhang","year":"2011","unstructured":"Zhang, H. et al. Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. Clin Chem. 57, 1005\u20131012 (2011).","journal-title":"Clin Chem."},{"key":"46829_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijcard.2011.06.097","volume":"158","author":"A Golda","year":"2012","unstructured":"Golda, A., Jurecka, A. & Tylki-Szymanska, A. Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). Int J Cardiol. 158, 6\u201311 (2012).","journal-title":"Int J Cardiol."},{"key":"46829_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2741\/4490","volume":"22","author":"P Harmatz","year":"2017","unstructured":"Harmatz, P. & Shediac, R. Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment. Front Biosci (Landmark Ed). 22, 385\u2013406 (2017).","journal-title":"Front Biosci (Landmark Ed)."},{"key":"46829_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10545-005-0069-y","volume":"28","author":"S Tomatsu","year":"2005","unstructured":"Tomatsu, S. et al. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis. 28, 743\u2013757 (2005).","journal-title":"J Inherit Metab Dis."},{"key":"46829_CR30","doi-asserted-by":"publisher","first-page":"471325","DOI":"10.1155\/2012\/471325","volume":"2012","author":"MF Coutinho","year":"2012","unstructured":"Coutinho, M. F., Lacerda, L. & Alves, S. Glycosaminoglycan storage disorders: a review. Biochem Res Int. 2012, 471325 (2012).","journal-title":"Biochem Res Int."},{"key":"46829_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgme.2018.05.004","volume":"125","author":"H Peracha","year":"2018","unstructured":"Peracha, H. et al. Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA. Mol Genet Metab. 125, 18\u201337 (2018).","journal-title":"Mol Genet Metab."},{"key":"46829_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ymgme.2016.11.007","volume":"120","author":"S Khan","year":"2017","unstructured":"Khan, S. et al. Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab. 120, 78\u201395 (2017).","journal-title":"Mol Genet Metab."},{"key":"46829_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF01799267","volume":"19","author":"H Northover","year":"1996","unstructured":"Northover, H., Cowie, R. A. & Wraith, J. E. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 19, 357\u2013365 (1996).","journal-title":"J Inherit Metab Dis."},{"key":"46829_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ajmg.a.36833","volume":"167A","author":"CJ Hendriksz","year":"2015","unstructured":"Hendriksz, C. J. et al. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A. 167A, 11\u201325 (2015).","journal-title":"Am J Med Genet A."},{"issue":"6","key":"46829_CR35","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/mgg3.471","volume":"6","author":"Hsiang-Yu Lin","year":"2018","unstructured":"Lin, H. Y. et al. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses. Mol Genet Genomic Med., https:\/\/doi.org\/10.1002\/mgg3.471 (2018).","journal-title":"Molecular Genetics & Genomic Medicine"},{"key":"46829_CR36","first-page":"15","volume":"64","author":"CK Chuang","year":"2001","unstructured":"Chuang, C. K., Lin, S. P. & Chung, S. F. Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. Zhonghua Yi Xue Za Zhi (Taipei). 64, 15\u201322 (2001).","journal-title":"Zhonghua Yi Xue Za Zhi (Taipei)."},{"key":"46829_CR37","first-page":"1","volume":"3","author":"CK Chuang","year":"2017","unstructured":"Chuang, C. K., Lin, H. Y., Wang, T. J., Huang, S. F. & Lin, S. P. Keratanase II Digestion Accompanied with a Liquid Chromatography\/Tandem Mass Spectrometry for Urinary Keratan Sulfate Quantitative Analysis. J Mucopolysacch. Rare Dis. 3, 1\u20138 (2017).","journal-title":"Rare Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46829-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:46:57Z","timestamp":1671277617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46829-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46829"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46829-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"18 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10755"}}